KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups

被引：0
|
作者：
Schmid, P. [1 ]
机构：
[1] Barts Canc Inst, Ctr Expt Med, London, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2020年 / 27卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P38
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Mouret-Reynier, Marie-Ange
    Ferreira, Marta
    Im, Seock-Ah
    Cardoso, Fatima
    Ding, Yu
    Pan, Wilbur
    Tryfonidis, Konstantinos
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [32] Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
    Loi, S.
    Schmid, P.
    Cortes, J.
    ark, Y. H.
    Munoz-Couselo, E.
    Kim, S-B
    Sohn, J.
    Im, S-A
    Holgado, E.
    Foukakis, T.
    Kuemmel, S.
    Dent, R.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) 1 chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Investigating the efficacy of fluoxetine vs. fluoxetine plus alprazolam (single therapy vs. combination therapy) in treatment of chronic tinnitus: A placebo-controlled study
    Saberi, Alia
    Nemati, Shadman
    Lili, Ehsan Kazemnejad
    Esmaeilpour, Hoda
    Panahi, Rasool
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 42 (03)
  • [35] Comparison of fluoxetine vs. fluoxetine plus tadalafil in the treatment of premature ejaculation - a double blind, placebo control study
    Culba, M.
    Ozkan, L.
    Ozkurkcugil, C.
    Gokalp, A.
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 : 60 - 61
  • [36] KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
    Bang, Yung-Jue
    Van Cutsem, Eric
    Fuchs, Charles
    Ohtsu, Atsushi
    Tabernero, Josep
    Ilson, David
    Hyung, Woo Jin
    Strong, Vivian
    Goetze, Thorsten
    Yoshikawa, Takaki
    Tang, Laura
    Sun, Linda
    Hasan, Aisha
    Koshiji, Minori
    Shitara, Kohei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [37] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [38] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [39] Rizatriptan vs. rizatriptan plus Trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo-controlled study
    Krymchantowski, AV
    Bigal, ME
    Moreira, PF
    NEUROLOGY, 2005, 64 (06) : A348 - A348
  • [40] Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study
    Krymchantowski, A. V.
    Filho, P. F. M.
    Bigal, M. E.
    CEPHALALGIA, 2006, 26 (07) : 871 - 874
12345